FDA IDE & Breakthrough Device Guide

IDE, study risk and Breakthrough designation

An Investigational Device Exemption (IDE) concerns investigation of a device in a clinical study under the applicable regulatory framework. Breakthrough Device designation is a separate development and review program. Neither decision is the eventual 510(k) clearance, De Novo grant or PMA approval needed for commercial marketing where applicable.

Start with the proposed study, patient population, device configuration and endpoints. A device's commercial risk class does not by itself decide the study's significant-risk status. Use FDA's IDE approval process and applicable Part 812 provisions.

Significant-risk, nonsignificant-risk and exempt investigations

A significant-risk study requires an FDA IDE and IRB approval before initiation. Nonsignificant-risk studies generally follow the abbreviated IDE requirements and IRB oversight without a separate FDA IDE application, unless FDA determines otherwise. Studies exempt from Part 812 must meet the exact exemption criteria; exemption from that part is not a universal exemption from human-subject protections or other applicable requirements.

The sponsor makes an initial risk assessment, the IRB reviews it, and FDA has the final authority. If uncertainty could change the development program, consider a study-risk determination Q-Submission. A Pre-Submission can address focused protocol and evidence questions before committing to the pivotal study.

Evidence to assemble before an IDE filing

Prepare a controlled description of the investigational device, prior investigations, risk analysis, manufacturing information, proposed protocol, monitoring, investigator arrangements, consent materials and investigational labeling as applicable. Connect endpoints and statistical analysis to the claims intended for the later marketing submission.

FDA's 30-day IDE framework must be read with the actual agency response and conditions. Do not start a significant-risk investigation merely because an application was sent, and do not treat a conditional approval as unrestricted permission for every protocol change. Track amendments, monitoring, reports and unanticipated adverse device effects under the applicable rules.

Breakthrough designation eligibility and timing

The Breakthrough Devices Program concerns devices that offer more effective treatment or diagnosis of life-threatening or irreversibly debilitating conditions and meet an additional statutory criterion, such as breakthrough technology, no approved/cleared alternative, significant advantages or availability in patients' best interest.

Request designation before the marketing submission through a designation Q-Submission. Present the device, indication, regulatory history, proposed pathway and evidence supporting each criterion. FDA describes a designation decision within 60 calendar days; that is not a promise of marketing authorization within 60 days. Designation supports prioritized interaction and review while the applicable safety and effectiveness standards remain.

Coordinate the development program

Maintain separate decisions for study risk, IDE/IRB readiness, designation eligibility and marketing pathway. Record unresolved clinical questions, evidence dependencies and responsibilities. Align eSTAR planning with the later submission, and budget study operations separately from regulatory review.